Sustainability relative to humans continuing to live on earth and beat a pandemic like COVID-19 requires a lot of logistical coordination and multi-national trade in many cases.
Sustaining adequate levels of Personal Protective Equipment - PPE In-stock is often very expensive, because so many overseas factories require paying form product either in advance or when it leaves the port to head to the US. Volume buyers do not typically like to have their money tied up for 30 or more days while product makes its way in shipping containers across the ocean. This is particularly true of Personal Protective Equipment (PPE) that is made in China.
Certain companies like PPE Source International, LLC proactively work with factories and key strategic partners to "land" the needed products in the US. This gives the large scale buyers, distributors, and resellers, the ability to shorten the time between payment from 30 days to 3 or 4 with ground shipping in the US. This PPE In-stock is an example of what has already landed and is being replenished on a weekly basis.
Here are just some of the "friction" factors that cone into play for importing products. With COVID-19, the importation has become even more complicated
- Bill of Entry:
- Commercial Invoice.
- Bill of Lading / Airway bill :
- Import License.
- Insurance certificate.
- Purchase order/Letter of Credit.
- Technical write up, literature etc. for specific goods if any.
- Industrial License if any.
All medical devices imported into the United States (U.S.) must meet the regulatory requirements of both the U.S. Bureau of Customs and Border Protection (CBP) and FDA. Products that do not meet FDA regulatory requirements may be detained upon entry.
CBP administers the Tariff Act of 1930 as amended. The primary duties include: assessment and collection of all duties, taxes, and fees on imported merchandise, administering and reviewing import entry forms, enforcing CBP and related laws, and administering certain navigation laws and treaties. FDA and CBP have an agreement for the cooperative enforcement of the Food, Drug, and Cosmetic Act, Section 801, Title 21 U.S.C. 381.
An entry for an FDA regulated product that is filed with CBP, will also be electronically submitted to FDA for review. An importer or customs broker is required to submit required entry information to CBP through the Automated Commercial Environment (ACE) system.